Biogen 2Q Revenues: $2.6 billion (+7%) 2Q Earnings: $927 million (+30%) FY Revenues: $5.1 billion (+13%) FY Earnings: $1.7 billion (+45%) Comments: Multiple sclerosis product sales were $2.1 billion compared to $2.0 billion in the same quarter last year. TECFIDERA revenues in the quarter increased 7% to $883 million. Interferon revenues, including AVONEX and PLEGRIDY, were $690 million, down 9%. TYSABRI revenues were $463 million, down 13%. Revenues relating to RITUXAN and GAZYVA...